Association of CSF GAP-43 and APOE ε4 with Cognition in Mild Cognitive Impairment and Alzheimer's Disease

被引:7
|
作者
Zhu, Yueli [1 ]
Guo, Xiaoming [2 ]
Zhu, Feng [1 ]
Zhang, Qin [1 ,3 ]
Yang, Yunmei [1 ,3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Geriatr, Hangzhou 310003, Peoples R China
[2] Tongde Hosp Zhejiang Prov, Dept Neurosurg, Hangzhou 310012, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Key Lab Diag & Treatment Aging & Phys Chem Injury, Hangzhou 310003, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; growth-associated protein 43; Apolipoprotein E epsilon 4; synaptic loss; biomarker; AMYLOID-BETA; SYNAPSE LOSS; PROTEIN; TAU; NEUROGRANIN; GENOTYPE; CA1;
D O I
10.3390/cells12010013
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The growth-associated protein 43 (GAP-43) is a presynaptic phosphoprotein in cerebrospinal fluid (CSF). The epsilon 4 allele of apolipoprotein E (APOE) is an important genetic risk factor for Alzheimer's disease (AD). We aimed to evaluate the association of CSF GAP-43 with cognition and whether this correlation was related to the APOE epsilon 4 status. We recruited participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, and they were divided into cognitively normal (CN) epsilon 4 negative (CN epsilon 4-), CN epsilon 4 positive (CN epsilon 4+), mild cognitive impairment (MCI) epsilon 4 negative (MCI epsilon 4-), MCI epsilon 4 positive (MCI epsilon 4+), AD epsilon 4 negative (AD epsilon 4-), and AD epsilon 4 positive (AD epsilon 4+) groups. Spearman's correlation was utilized to evaluate the relationship between CSF GAP-43 and core AD biomarkers at the baseline. We performed receiver-operating characteristic (ROC) curve analyses to investigate the diagnostic accuracy of CSF GAP-43. The correlations between CSF GAP-43 and the Mini-Mental State Examination (MMSE) scores and brain atrophy at baseline were assessed by using multiple linear regression, while the association between CSF GAP-43 and MMSE scores at the follow-up was tested by performing the generalized estimating equation (GEE). The role of CSF GAP-43 in the conversion from MCI to AD was evaluated using the Cox proportional hazard model. We found that the CSF GAP-43 level was significantly increased in MCI epsilon 4+, AD epsilon 4- and AD epsilon 4+ groups compared with CN epsilon 4- or MCI epsilon 4- group. The negative associations between the CSF GAP-43 and MMSE scores at the baseline and follow-up were found in MCI epsilon 4- and MCI epsilon 4+ groups. In addition, baseline CSF GAP-43 was able to predict the clinical progression from MCI to AD. CSF GAP-43 may be a promising biomarker to screen cognition for AD. The effects of CSF GAP-43 on cognition were suspected to be relevant to APOE epsilon 4 status.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Is mild cognitive impairment bridging the gap between normal aging and Alzheimer's disease?
    Smith, G
    AGEING AND DEMENTIA CURRENT AND FUTURE CONCEPTS, 2002, : 97 - 104
  • [42] Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease
    Mandecka, Monika
    Budziszewska, Magdalena
    Barczak, Anna
    Peplonska, Beata
    Chodakowska-Zebrowska, Malgorzata
    Filipek-Gliszczynska, Anna
    Nesteruk, Marta
    Styczynska, Maria
    Barcikowska, Maria
    Gabryelewicz, Tomasz
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (01) : 157 - 168
  • [43] Cognitive Impairment Associated with APOE Biomarkers in Alzheimer's Disease
    Diah, K.
    Vitale, G.
    Keith, M.
    Fornalski, N.
    Golden, C.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2017, 32 (06) : 668 - 668
  • [44] Cognitive complaint in mild cognitive impairment and Alzheimer's disease
    Clement, Francis
    Belleville, Sylvie
    Gauthier, Serge
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2008, 14 (02) : 222 - 232
  • [45] Cognitive impairment in Alzheimer's disease is modified by APOE genotype
    van der Vlies, Annelies E.
    Pijnenburg, Yolande A. L.
    Koene, Teddy
    Klein, Martin
    Kok, Astrid
    Scheltens, Philip
    van der Flier, Wiesje M.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2007, 24 (02) : 98 - 103
  • [46] Vascular Disease, Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment: Additive or Synergetic Effects?
    Nordlund, Arto
    Gothlin, Mattias
    Wallin, Anders
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2011, 32 (04) : 250 - 256
  • [47] Pathophysiological subtypes of mild cognitive impairment due to Alzheimer's disease identified by CSF proteomics
    Moutinho, Daniela
    Mendes, Vera M.
    Caula, Alessandro
    Madeira, Sara C.
    Baldeiras, Ines
    Guerreiro, Manuela
    Cardoso, Sandra
    Gobom, Johan
    Zetterberg, Henrik
    Santana, Isabel
    De Mendonca, Alexandre
    Aidos, Helena
    Manadas, Bruno
    TRANSLATIONAL NEURODEGENERATION, 2024, 13 (01)
  • [48] CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease
    Kaiser, E.
    Schoenknecht, P.
    Hunt, A.
    Thomann, P. A.
    Pantel, J.
    Schroeder, J.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2008, 41 (06): : 497 - 501
  • [49] CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease
    Fjell, Anders M.
    Walhovd, Kristine B.
    Fennema-Notestine, Christine
    McEvoy, Linda K.
    Hagler, Donald J.
    Holland, Dominic
    Brewer, James B.
    Dale, Anders M.
    JOURNAL OF NEUROSCIENCE, 2010, 30 (06): : 2088 - 2101
  • [50] CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease
    Samuels, SC
    Silverman, JM
    Marin, DB
    Peskind, ER
    Younki, SG
    Greenberg, DA
    Schnur, E
    Santoro, J
    Davis, KL
    NEUROLOGY, 1999, 52 (03) : 547 - 551